Peripheral Artery Disease (PAD)

This channel includes news, interventions, and new technology innovations for peripheral artery diease, PAD and critical limb ischemia. 

News | Peripheral Artery Disease (PAD)

June 7, 2021 — A couple years ago a study showed a mortality safety signal in patients who underwent peripheral artery ...

Home June 07, 2021
Home
News | Peripheral Artery Disease (PAD)

May 17, 2021 — The anticoagulant rivaroxaban (Xarelto), in addition to low-dose aspirin, significantly reduced the ...

Home May 17, 2021
Home
News | Venous Therapies

February 22, 2021 — The U.S. Food and Drug Administration (FDA) recently cleared the Cook Medical Zilver Vena Venous ...

Home February 22, 2021
Home
News | Cardiovascular Business

February 3, 2021 — Modern Vascular is a medical group that has 13 outpatient cath lab clinics to treat peripheral artery ...

Home February 03, 2021
Home
News | Peripheral Artery Disease (PAD)

January 26, 2021 — Pedra Technology, a privately held company, announced today that the U.S. Food and Drug ...

Home January 26, 2021
Home
News | Stents Bioresorbable

December 16, 2020 — Efemoral Medical announced the first-in-human (FIH) use of the its Efemoral bioresorbable vascular ...

Home December 16, 2020
Home
News | Peripheral Artery Disease (PAD)

November 13, 2020 — The new U.S. Food and Drug Administration (FDA) cleared XO Score system was successfully used to ...

Home November 13, 2020
Home
News | Drug-Eluting Balloons

November 3, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the Boston Scientific Ranger Drug-coated ...

Home November 03, 2020
Home
Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the  Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip. Acurate neo TAVR valve. #TCTconnect #TCT2020
Feature | TCT | Dave Fornell, Editor

Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials ...

Home October 29, 2020
Home
A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab

October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benefit ...

Home October 18, 2020
Home
News | Drug-Eluting Balloons

October 18, 2020 – The first results from the IN.PACT Below the Knee (BTK) Study, a feasibility study assessing the ...

Home October 18, 2020
Home
News | Thrombectomy Devices

September 25, 2020 — Philips Healthcare launched its QuickClear mechanical thrombectomy system. The compact, single-use ...

Home September 25, 2020
Home
News | Chronic Total Occlusion (CTO)

September 14, 2020 — Avinger received U.S. Food and Drug Administration (FDA) 510(k) clearance from the FDA for its ...

Home September 14, 2020
Home
News | Peripheral Artery Disease (PAD)

September 4, 2020 — The U.S. Centers for Medicare and Medicaid Services (CMS) granted a New Technology Add-on Payment ...

Home September 04, 2020
Home
Abbott Espirit BTK Bioresorbable stent, or bioresorbable vascular scaffold (BVS) measures 99 microns and is made from poly-L-lactide (PLLA), a semi-crystalline bioresorbable polymer engineered to resist vessel recoil and provide a platform for drug delivery. Abbott Absorb
Feature | Stents Bioresorbable

September 3, 2020 — Abbott today announced the start of the LIFE-BTK clinical trial to evaluate the safety and ...

Home September 03, 2020
Home
Subscribe Now